An Investigational Scan (111In-ABD147 SPECT/CT) for the Imaging of Metastatic Prostate, Neuroendocrine, or other Solid Tumors
This early phase I trial evaluates a new imaging technique (111In-ABD147 single photon emission computed tomography [SPECT]/computed tomography [CT]) for diagnosing prostate, neuroendocrine, or other solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). 111In-ABD147 is an imaging agent that contains an antibody linked to a radioactive isotope of an element called indium. When 111In-ABD147 is infused, the antibody fragment binds to a marker called DLL3, which is expressed by some types of tumor cells. The radioactive isotope can then be visualized with certain types of imaging scans, such as CT, to identify areas in the body where the antibody is binding to tumor cells. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. SPECT is a special type of CT scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells. SPECT/CT is a dual-modality imaging technique that combines data from SPECT and CT to provide structural and functional information. 111In-ABD147 SPECT/CT may be a safe and effective imaging technique for diagnosing metastatic prostate, neuroendocrine, or other solid tumors.